Newsletter No. 2, 2021

ChloraSolv01 study soon to be published in Journal of Wound Care

As communicated previously, RLS has submitted the clinical trial ChloraSolv01 to high ranked scientific journals to be reviewed and evaluated for publication. It is now confirmed that Journal of Wound Care has approved the data and will publish the publication in the issue of July 2021.

Journal of Wound Care is one of the most established magazines in the wound management community and it is a great recognition to ChloraSolv01 and the clinical outcome. The publication has been reviewed by an external editorial board and accepted. The article will have an open access, so anyone can get access to the results when published.

Highlights from the study were presented at the EWMA 2020 virtual conference. It was found that after only six treatments/debridements with ChloraSolv, 71,4% of the patients had a reduction of 50% or more of devitalized tissue. The study showed low pain score in general. The reduction of devitalized tissue was an average of -72,7%. At the same time, the wound size reduction was -30,9%.

Ease of use and time are two very important key components if the aim is to establish a new technology as a standard of care. In the ChloraSolv study these areas were evaluated by the care givers. The tables below summarize the questions and the percentage outcome:














An overall evaluation by the investigators/nurses showed that 68,9% of the responders agree that ChloraSolv debridement gel makes the debridement easier than previously used debriding treatments, whereas only 3,8% do not agree.

Also to be mentioned, the investigation showed that debridement in conjunction with the use of ChoraSolv was well tolerated and efficient. Most of the investigators/nurses found that debridement was easier performed with ChloraSolv than treatments previously used.

It is a very strong recognition that ChloraSolv has been accepted by Journal of Wound Care and will be published within the next few months. Journal of Wound Care is one of the most respected journals in the wound management community.

Finally, I would like to welcome you to ChloraSolv Academy. ChloraSolv Academy is a platform and forum where RLS gathers stakeholders in advanced wound care with the aim to sharing knowledge, experience and clinical data related to research for patients with difficult to heal wounds. Our focus area is good wound debridement required to support effective wound healing. At present, the website is available in Swedish:

ChloraSolv Academy – Allt du behöver veta om debridering

I hope you will take some time and review all the information available at ChloraSolv Academy.


Karin Fischer
CEO RLS Global